奥芬达唑治疗成人鞭虫感染的疗效
不同剂量奥芬达唑与单剂量阿苯达唑治疗成人鞭虫感染疗效的盲法、随机、比较研究
The main objective of this study is to provide data on the efficacy profile of different doses of oxfendazole when used in Trichuris trichiura infection. The drug will be also be examined for efficacy against other common nematodes encountered in man (Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus). The study will also provide data on the safety and tolerability of the oxfendazole in patients.
研究概览
详细说明
This is an assessor blind, randomized, comparative study in adult patients with proven intestinal infection with Trichuris trichiura to be conducted as a field study. Patients meeting the study entry criteria will receive either 6 mg/kg or 15 mg/kg or 30 mg/kg of oxfendazole as a single oral dose, three single doses of oxfendazole on consecutive days, or albendazole 400mg as a single oral dose. Stool samples will be obtained and examined prior to treatment and at 7, 14 and 21 days after treatment.
研究类型
阶段
- 阶段2
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female outpatient, more than 18 years and less than 65 years of age.
- Written or witnessed oral informed consent has been obtained.
- Trichuris trichiura demonstrated in stool samples obtained during the week before enrolment: The presence of Ascaris lumbricoides, Necator americanus, Ancylostoma duodenalis or other helminths will not be a cause for exclusion.
- Willingness to comply with the requirements of the protocol and particularly to provide 4 stool samples, pretreatment and 7, 14 and 21 days after treatment.
- Female patients of child bearing potential, who are using an established method of birth control (surgically sterile, intra-uterine contraceptive device, oral contraceptives, diaphragm in combination with contraceptive cream or foam, or condom in combination with contraceptive cream or foam) may be included
Exclusion Criteria:
- The patient has demonstrated a previous hypersensitivity reaction to benzimidazole or other related compound.
- Presence of other helminths without Trichuris trichiura. Non-target species may be present and details of response will be recorded.
- The patient has diarrhoeal disease that would interfere with the evaluation of stool samples.
- The patient has received an anthelminthic in the 2 weeks prior to enrolment into the study.
- The patient has received an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit or is scheduled to receive such a drug during the study period.
- The patient has a concomitant infection or any other underlying disease that would compromise the diagnosis and the evaluation of the response to the study medication.
- The patient has a known history of renal dysfunction or plasma creatinine ≥ 1.5 times upper limit of normal for age or a known history of hepatic dysfunction or liver enzymes ≥ 1.5 times upper limit of normal.
- The patient is a female who is pregnant, lactating or planning a pregnancy during the study, or is not practicing any form of contraception (see inclusion criteria (4.2.5).
- The patient is unwilling or unable to take part in this study.
- The patient has previously been enrolled in the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:OXF6
Patients receive a single 6 mg/kg dose of oxfendazole administered orally. |
oral suspension |
|
实验性的:OXF15
Patients receive a single 15 mg/kg dose of oxfendazole administered orally. |
oral suspension |
|
实验性的:OXF30
Patients receive a single 30 mg/kg dose of oxfendazole administered orally. |
oral suspension |
|
实验性的:OXF15x3
Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days. |
oral suspension |
|
有源比较器:ALB400
Patients receive a single 400 mg/kg dose of albendazole administered orally. |
tablet |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
cure d14
大体时间:Day 14 of follow up
|
absence of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 14 of follow up
|
|
cure d7
大体时间:Day 7 of follow up
|
absence of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 7 of follow up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
improvement d21
大体时间:Day 21 of follow up
|
reduction (with respect to the baseline count of that individual) in number of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 21 of follow up
|
|
improvement d14
大体时间:Day 14 of follow up
|
reduction (with respect to the baseline count of that individual) in number of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 14 of follow up
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d7
大体时间:Day 7 of follow up
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Day 7 of follow up
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d14
大体时间:Day 14 of follow up
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Day 14 of follow up
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d21
大体时间:Day 21 of follow up
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Day 21 of follow up
|
合作者和调查者
调查人员
- 首席研究员:Héctor Hugo Garcia, MD PhD、Oxfendazole Development Group
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- OXF2 v3.21
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data will be uploaded to the clinicaltrials.gov website, and a publication will be prepared
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.